Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Researchers from the University of Oxford are collaborating in a project that will enable registered researchers from across the world to analyse population-scale genomic and biomolecular data, using the Common Infrastructure for National Cohorts in Europe, Canada and Africa (CINECA).

Oxford University’s contribution is led by Professor Mark McCarthy (who is based in the Oxford Centre for Diabetes, Endocrinology and Metabolism, and the Wellcome Centre for Human Genetics).

Read more (Radcliffe Department of Medicine website)

Similar stories

Ancient gene mutation found to cause rare hereditary condition

General Research

UK scientists have found that a 7,000-year-old genetic mutation is responsible for a rare form of hereditary motor neuropathy (HMN).

National consortium to study threats of new SARS-CoV-2 variants

Coronavirus COVID-19 General Research

A new national research project to study the effects of emerging mutations in SARS-CoV-2 will be launched with £2.5 million funding from UK Research and Innovation (UKRI).

Immunology preprint reviews launched in Nature Reviews Immunology

General Research

The Oxford-Mount Sinai (OxMS) Preprint Journal Club has partnered with Nature Reviews Immunology to launch a monthly Preprint Watch column.

No limit to the benefits of exercise in reducing the risk of cardiovascular disease

General Research

A new study led by the University of Oxford on over 90,000 participants shows that there is no upper threshold to the benefits of exercise in reducing the risk of cardiovascular disease – ‘every move counts towards better cardiovascular health.’

Accurate predictions of ovarian cancer outcome possible with new classification system

General Research

The new, Oxford-developed method for subtyping ovarian cancer has been validated in a recent collaboration between the University of Oxford and Imperial College London. Dubbed the ‘Oxford Classic’, researchers have demonstrated that it enables the accurate prediction of patient disease outcome, as well as the development of new targeted cancer therapies.